Good morning, and welcome to Agenus Inc.'s fourth-quarter and year-end 2024 earnings conference call. Currently, all ...

Agenus (AGEN) shares slipped in morning trade after the company missed fourth quarter revenue estimates. The company reported ...

Q4 2024 Earnings Call Transcript March 11, 2025 Agenus Inc. beats earnings expectations. Reported EPS is $-2.04, expectations ...

Agenus Inc (AGEN) reports reduced operational burn and promising clinical developments, despite a significant net loss and ...

Baird lowered the firm’s price target on Agenus (AGEN) to $3 from $6 and keeps a Neutral rating on the shares. The firm updated its model ...

Agenus Inc. (“Agenus” or the “Company”) (Nasdaq: AGEN), an immuno-oncology company advancing innovative cancer therapies, ...

LEXINGTON, Mass. (AP) — LEXINGTON, Mass. (AP) — Agenus Inc. (AGEN) on Tuesday reported a loss of $46.8 million in its fourth quarter. The Lexington, Massachusetts-based company said it had a loss of ...

Reports Q4 revenue $26.84M, consensus $30.09M. “In line with our strategic objectives, we significantly reduced our annualized operational burn ...

Agenus (AGEN) delivered earnings and revenue surprises of 13.56% and 20.21%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Checkpoint inhibitors are drugs that harness the immune system to destroy cancer cells. Let us review what’s been going on in the field.

Agenus Inc. (NASDAQ:AGEN – Get Free Report) has earned a consensus rating of “Hold” from the six brokerages that are ...